Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation
NCT02305329 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56
Last updated 2015-08-21
Summary
Single-centre, open-label, randomized, two-sequence, two-way crossover study. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 10 to 14 days or more.
Conditions
Interventions
- DRUG
-
BIA 9-1067
Sponsors & Collaborators
-
Bial - Portela C S.A.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-02-28
- Primary Completion
- 2014-04-30
- Completion
- 2014-04-30
More Related Trials
-
A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093
NCT02171195 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
NCT02172755 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
NCT02279667 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures
NCT01162460 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
NCT00900237 ·Status: COMPLETED ·Phase: PHASE1
-
A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093
NCT02171234 ·Status: COMPLETED ·Phase: PHASE1
-
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
NCT01702623 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
NCT01167335 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093
NCT02170649 ·Status: COMPLETED ·Phase: PHASE1
-
Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.
NCT02283827 ·Status: COMPLETED ·Phase: PHASE1
-
A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate
NCT02283814 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin
NCT02287415 ·Status: COMPLETED ·Phase: PHASE1
-
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093
NCT02170077 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
NCT02736162 ·Status: COMPLETED
-
An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
NCT02281422 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy
NCT01079351 ·Status: COMPLETED ·Phase: PHASE1
-
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
NCT03059329 ·Status: COMPLETED
-
Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine
NCT02281591 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
NCT00961441 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
NCT02535091 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
NCT07198035 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
NCT02777671 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
NCT01527513 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers
NCT01879345 ·Status: COMPLETED ·Phase: PHASE1